Abstract: The present invention provides the novel anti-IRC85 monoclonal antibody specifically binding with IRC85 and it showed potent effect in removing the infected/phagocytosed bacteria from THP-I, a monocytic cell that expresses human IRC85 and is infected with Listeria monocytogenes or WR-tubercle bacillus. Accordingly, it can be useful as a medicament and health care food in the prevention and treatment of tuberculosis disease and enteritis disease.

Abstract: Provided are methods of isolating and proliferating antigen-specific CD8+ T cells using anti-4-1BB antibodies. The methods of isolating and proliferating CD8+ T cells may yield cells at a higher recovery rate than a conventional isolation method, and the isolation method using humanized anti-4-1BB antibodies may also yield cells at a high recovery rate. Further, in cell culture, cells may be grown at a high proliferation rate. The antigen-specific CD8+ T cells yielded according to the isolation and proliferation methods may be used to treat cancer without any side-effects.

Abstract: The present invention provides the novel anti-IRC85 monoclonal antibody specifically binding with IRC85 and it showed potent effect in removing the infected/phagocytosed bacteria from THP-I, a monocytic cell that expresses human IRC85 and is infected with Listeria monocytogenes or WR-tubercle bacillus. Accordingly, it can be useful as a medicament and health care food in the prevention and treatment of tuberculosis disease and enteritis disease.

Abstract: The present invention is related to a pharmaceutical composition comprising humanized anti-4-1BB antibody (HBBK4) for treating cancer by inducing increase of CD11+CD8+ T cell and IFN-?, and inhibiting proliferation of cancer cells, together with a pharmaceutically acceptable carrier and the use. Accordingly, it can be useful in the prevention or treatment of cancer without adverse response.

Abstract: The present invention is related to a pharmaceutical composition comprising humanized anti-4-1BB antibody (HBBK4) for treating cancer by inducing increase of CD11+CD8+ T cell and IFN-?, and inhibiting proliferation of cancer cells, together with a pharmaceutically acceptable carrier and the use. Accordingly, it can be useful in the prevention or treatment of cancer without adverse response.

Abstract: Provided are methods of isolating and proliferating antigen-specific CD8+ T cells using anti-4-1BB antibodies. The methods of isolating and proliferating CD8+ T cells may yield cells at a higher recovery rate than a conventional isolation method, and the isolation method using humanized anti-4-1BB antibodies may also yield cells at a high recovery rate. Further, in cell culture, cells may be grown at a high proliferation rate. The antigen-specific CD8+ T cells yielded according to the isolation and proliferation methods may be used to treat cancer without any side-effects.

Abstract: A combined composition comprising an anti-4-1BB monoclonal antibody and chemotherapeutic anti-cancer agent for preventing and treating cancer disease. Provides a pharmaceutical composition comprising the combined mixture of anti-4-1BB antibody and chemotherapeutic anti-cancer agent enhancing the specific immune response to cancer and killing cancer cell for treating or preventing cancer disease as an effective ingredient, together with a pharmaceutically acceptable carrier.

Abstract: The present invention is related to a pharmaceutical composition comprising anti-4-1BB antibody as an active ingredient in an amount effective to preventing and treating rheumatic arthritic diseases by proliferating CD1 Ic+CD8+ T cells and inducing CD4+ T cell suppression, together with a pharmaceutically acceptable carrier. The composition of the present invention is not toxic in general immune response and can remarkably alleviate progressive, inflammatory or auto-immune arthritis symptoms by inducing antigen-specific immune suppression. Accordingly, it can be useful in the prevention or treatment of arthritic diseases without adverse response.

Abstract: Full length cDNAs, L2G25B and 4-1BB, were isolated and sequenced. The cDNA L2G25B encodes for the lymphokine, macrophage inflammatory protein-1&agr; or MIP-1&agr;. The studies disclosed herein suggest that MIP-1&agr; and MIP-&bgr; can, through rapid action, modulate early myeloid progenitor cell proliferation. Recombinant proteins have been produced for the cytokine, L2G25BP (Macrophage Inflammatory Protein-1&agr;, MIP-1&agr;). By employing the recombinant protein (rMIP-1&agr;), receptors for MIP-1&agr; were identified on Con A-stimulated and unstimulated CTLL-R8, a T-cell line, and LPS-stimulated RAW 264.7, a macrophage-cell line. Purified recombinant murine macrophage inflammatory protein-1 alpha (rmuMIP-&agr;), was assessed for effects on proliferation of granulocyte-macrophage (CFU-GM), erythroid (BFU-E), and multipotential (CFU-GEMM) progenitor cells. The results suggest that rmuMIP-1&agr; has myelosuppressive activity in vivo.

Abstract: The present invention started when a .lambda.gt11 cDNA library of normal human melanocytes was screened with antibodies directed against purified hamster tyrosinase. Two important cDNA clones were isolated: cDNA .lambda.mel 34 and .lambda.mel 17-1. It is concluded that .lambda.mel 34 contained cDNA encoding human tyrosinase. Moreover, the cDNA gene for human tyrosinase was recovered from the .lambda.mel 34 and can be used for many purposes including the production of pure human tyrosinase. This gene and its promoter are characterized herein. Studies suggested that .lambda.mel 17-1 gene product act on melanin biosynthesis's pathway distal to tyrosinase. Melanocytes preferentially express an mRNA species, Pmel 17, whose protein product cross reacted with anti-tyrosinase antibodies and whose expression correlated with the melanin content. The deduced protein structure has been analyzed and its chromosomal location in mouse and man has been mapped.